ALIVE is an Israel HealthTech Fund that leverages its ecosystem to drive and accelerate the long-term growth of Israel's HealthTech technologies.

ALIVE

ALIVE is a mid-to-late stage HealthTech fund, leveraging an exclusive ecosystem of strategic partnerships consisting of hospital chains, HMOs and financial institutions, to support and accelerate portfolio companies in their clinical and commercial expansion.


ALIVE Israel HealthTech Fund

Lightning strikes twice for ALIVE!
From a massive exit announcement
to a game-changing investment round - all in less than a week

𝐰𝐞 𝐡𝐚𝐯𝐞 𝐠𝐫𝐞𝐚𝐭 𝐧𝐞𝐰𝐬!
Magenta Medical Ltd.  our portfolio company, 
has secured $105M in funding, led by global investor Novo Holdings!

This round, which is the largest of 2024 for Israeli Medtech companies, also includes investments from top-tier crossover funds Viking Global Investors and RA Capital Management, alongside existing investors- OrbiMed, JVC Investment Partners, NEA, and ALIVE.


Magenta's Elevate™ is the world’s smallest, highest-performance, catheter-delivered heart pump, a groundbreaking tech set to revolutionize cardiac care, for conditions like cardiogenic shock and high-risk cardiac procedures.


Key Highlights:

→ Tech at the Forefront: Elevate™ offers unparalleled mechanical heart support, promising better care for severe heart disease patients.

→ Strong Partnerships: With giants like Viking and RA Capital on board, Magenta is poised for substantial value growth.

→ Growth Plan: Funds will support US EFS and FDA pivotal studies, targeting cardiogenic shock and high-risk cardiac indications.


Dr. David Israeli, MD, CEO of Magenta, emphasized: 
“With top-tier investors and our existing partners, we’re ready to scale up our clinical programs and enhance cardiac care.”


Magenta is ready to make waves in the cardiac support device market, bringing innovative and life-saving technology to patients worldwide, and it’s our privilege to be an active part of this journey.

ועכשיו גם בעברית :)
מתרגשים להכריז על אקזיט ראשון של מעל 300 מיליון דולר בפחות מ-4 שנים בחברת Innovalve !

גאים ושמחים לשתף על אקזיט ישראלי ראשון ענק של חברת הפורטפוליו שלנו, Innovalve Bio Medical Ltd.. אשר  נרכשה על ידי Edwards Lifesciences תמורת למעלה מ-300 מיליון דולר!
חברת אינוולב ביו מדיקל מפתחת פתרונות מתקדמים לטיפול חדשני ובטוח יותר בתחלואה של מסתמי הלב באופן זעיר פולשני. אדוורדס היא אחת השחקניות החשובות והמובילות בעולם בתחום המכשור הרפואי ללב. 
עסקת הרכישה היא הבעת אמון חסרת תקדים של חברת ענק אמריקאית בטכנולוגיה ישראלית שתגיע למיליוני מטופלים ברחבי העולם, תציל חיים רבים ותשפר את רפואת הלב ברמה הגלובלית.
במילותיו של  Michel Habib, שותף מייסד בקרן וחבר דירקטוריון ב-Innovalve:
 "שותפיי ואני גאים על האקזיט הראשון של קרן ALIVE, שהושג על בסיס מימוש אסטרטגית ההשקעה הייחודית והממוקדת של הקרן ליצירת ערך משמעותי בחברות מדיקל מבטיחות. 
אינוולב היא דוגמא ומופת לטכנולוגיה ישראלית פורצת דרך מבית היוצר של טובי הרופאים והממציאים בישראל, שהפכה להצלחה מוצרית וקלינית ברמה בינלאומית בתמיכה פעילה של הבורד והמשקיעים שלה לאורך כל הדרך, עד למכירתה לחברה המובילה בעולם בתחום מסתמי הלב״.
תודה למשקיעים שלנו, לשותפים, ולצוות המדהים של Innovalve שהפכו את ההישג הזה לאפשרי.

****
קרן Alive מתמקדת בהשקעות בחברות בשלות בתחום הטכנולוגיה הרפואית:
← חוגגים אקזיט ראשון בפחות מ-4 שנים. 
← הפורטפוליו שלנו כולל 12 חברות מבטיחות (לדוגמה, Magenta Medical Ltd., Navina , Cynerio). 
← בימים אלו אנו מגייסים את קרן ההמשך שתמשיך להשקיע באסטרטגיה דומה בחברות מתקדמות בתחום הבריאות.

First Major Exit - Over $300M in Less Than 4 Years! 

We're incredibly proud to share that our portfolio company, Innovalve Bio Medical Ltd. has been acquired by Edwards Lifesciences  for over 300 $ million!

Innovalve is a leading medical device company developing unique Transcatheter Mitral Valve Replacement (TMVR) technology. Invented at Sheba Medical Center, Israel's largest hospital, Innovalve is pioneering catheter-delivered heart valve therapies that promise to revolutionize cardiac care.

Edwards Lifesciences, a global leader in heart care medical devices, has shown unprecedented confidence in this Israeli technology. 

This acquisition has the potential to reach millions of patients worldwide, save countless lives, and significantly improve global cardiac care. 

It's a testament to the power of Israeli innovation in healthcare.

In the words of Michel Habib  Founding Partner & Innovalve Board Member:

“My partners and I are proud of achieving ALIVE Fund's first exit, based on our unique and focused investment strategy aimed at creating significant value in promising medical companies. 
Innovalve is a prime example of breakthrough Israeli technology developed by the best doctors and inventors in Israel, which has become a product and clinical success internationally with the active support of its board and investors throughout, leading to its sale to the world's leading company in heart valve technology."

Thank you to our investors, partners, and the incredible Innovalve team for making this possible.

Here's to advancing Israeli HealthTech and improving global healthcare! 


***
Alive focuses on investments in mature companies in the medical technology sector:
→ Exit achieved in under 4 years
→ Our portfolio includes 12 promising companies (e.g., Magenta Medical Ltd.  Navina  Cynerio 
→ Now raising the next fund for continued investment in advanced healthcare technologies.

In the midst of challenging times for Israel, we'd like to share a moment of pride and optimism, as we celebrate today ALIVE's 4th anniversary of investing in innovation and growth in Israel's vibrant HealthTech industry! 
We are grateful for the great partners and team who've been part of our journey. 

Cheers to continued success and impact in the years ahead! 🥂 
#VentureCapital #HealthTech #Innovation

🌟 We are thrilled to share that one of our portfolio companies, Navina, has been honored with the prestigious "Best Overall Health Informatics Solution" award at the 8th annual MedTech Breakthrough Awards! 🏆 
 
This recognition underscores Navina's commitment to transforming primary care through AI technology. It highlighted Navina's innovation for enabling physicians to optimize their clinical workflows, foster patient trust, and excel in value-based care. 
We are immensely proud of Navina's achievement and appreciate the exceptional team! 🙌 
 

 Learn more about Navina's groundbreaking work: https://lnkd.in/dm3mKMPA 

#HealthTech #AI #Innovation #ValueBasedCare

Metric
Company Name	ALIVE
Symbol
MSH ID	COM:ALIVEVC
Market	PRIVATE
Sector	Financial Services & Finance
Industry	Venture Capital
Country	IL
Stage
Employee Count	7
Website	alivevc.com
LinkedIn	alivevc
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

ALIV

COM:ALIVEVC

ALIVE

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue